2024
2023
Williams MJ, Okai AF, Cross AH, Monson NL, Vartanian T, Thrower BW, Reder AT, English JB, Wu GF, Bernitsas E et al..
2023. Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial.. Mult Scler Relat Disord. 76:104794.
2022
Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ.
2022. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.. CNS Drugs. 36(9):977-993.
2021
Lavette LE, Miller A, Rook B, London Z, Cook C, Merkler AE, Santini V, Ruff IMarie, Kraakevik J, Smith D et al..
2021. Education Research: NeuroBytes: A New Rapid, High-Yield e-Learning Platform for Continuing Professional Development in Neurology.. Neurology. 97(8):393-400.
Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D et al..
2021. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.. Adv Ther. 38(7):3724-3742.
2020
2019
Cheung JW, Cheng EP, Wu X, Yeo I, Christos PJ, Kamel H, Markowitz SM, Liu CF, Thomas G, Ip JE et al..
2019. Sex-based differences in outcomes, 30-day readmissions, and costs following catheter ablation of atrial fibrillation: the United States Nationwide Readmissions Database 2010-14.. Eur Heart J. 40(36):3035-3043.
Guo H, Kommidi H, Maachani UB, Voronina JC, Zhang W, Magge RS, Ivanidze J, Wu AP, Souweidane MM, Aras O et al..
2019. An [18F]-Positron Emitting Fluorophore Allows Safe Evaluation of Small Molecule Distribution in the CSF, CSF Fistulas, and CNS Device Placement.. Mol Pharm. 16(8):3636-3646.
Sandrone S, Berthaud JV, Carlson C, Cios J, Dixit N, Farheen A, Kraker J, Owens JWM, Patino G, Sarva H et al..
2019. Education Research: Flipped classroom in neurology: Principles, practices, and perspectives.. Neurology. 93(1):e106-e111.
Ramasamy S, Yaghi S, Omran SSalehi, Lerario MP, Devereux R, Okin PM, Gupta A, Navi BB, Kamel H, Merkler AE.
2019. Association Between Left Ventricular Ejection Fraction, Wall Motion Abnormality, and Embolic Stroke of Undetermined Source.. J Am Heart Assoc. 8(9):e011593.
2018
Pillai RLI, Malhotra A, Rupert DD, Weschler B, Williams JC, Zhang M, Yang J, J Mann J, Oquendo MA, Parsey RV et al..
2018. Relations between cortical thickness, serotonin 1A receptor binding, and structural connectivity: A multimodal imaging study.. Hum Brain Mapp. 39(2):1043-1055.
2017
2016
Zhang Y, Gauthier SA, Gupta A, Chen W, Comunale J, Chiang GC-Y, Zhou D, Askin G, Zhu W, Pitt D et al..
2016. Quantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation.. AJNR Am J Neuroradiol. 37(9):1629-35.
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al..
2016. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.. Contemp Clin Trials. 50:166-77.
2015
2014
Isaacson RS, Haynes N, Seifan A, Larsen D, Christiansen S, Berger JC, Safdieh JE, Lunde AM, Luo A, Kramps M et al..
2014. Alzheimer's Prevention Education: If We Build It, Will They Come? www.AlzU.org. J Prev Alzheimers Dis. 1(2):91-98.
2013
2012
1992
1987
1986
1984
1983
1982
1981
1980
1979
1978
1977
1976
1975
1974
1973
1972
1971
1970
1967